PAX1 Methylation as a Potential Biomarker to Predict the Progression of Cervical Intraepithelial Neoplasia: A Meta-analysis of Related Studies
PAX1 Methylation as a Potential Biomarker to Predict the Progression of Cervical Intraepithelial Neoplasia: A Meta-analysis of Related Studies
复制标题
PAX1甲基化作为预测宫颈上皮内瘤变进展的潜在生物标志物：相关研究的荟萃分析
DOI：
10.1097/igc.0000000000001011
复制
发表时间：
2017-09-01
影响因子：
4.8
通讯作者：
Li, Ping
中科院分区：
文献类型：
--
作者：
Luan, Ting;Hua, Quan;Li, Ping
目的配对盒基因1 （PAX1）甲基化对宫颈病变过程有重要影响。然而，PAX1甲基化与宫颈上皮内瘤变（CIN）之间的关联的现有证据并不一致。在这里，我们系统地回顾和分析了CIN中PAX1甲基化的进展。方法两位研究者独立检索了PubMed、Cochrane Library、EMBASE和Web of Science数据库中截至2016年11月30日发表的符合条件的PAX1甲基化和CIN研究。我们提取了与PAX1甲基化相关的CIN和宫颈取消的临床病理特征。比值比（ORs）及其95%置信区间（CIs）用于评估PAX1甲基化与CIN患者进展之间的关系。结果最终纳入7项研究，共1055例不同分期CIN和宫颈取消患者。结果显示，PAX1甲基化与CIN I向CIN II/III的转变（OR, 0.09; 95% CI, 0.04-0.19）和CIN II/III向宫颈癌的转变（OR, 0.16; 95% CI, 0.05-0.46）有关，敏感性分析也得出了类似的结果。此外，我们发现OR值与纳入文章的平均年龄和患者数量、发表年份和研究地点有关。结论PAX1基因甲基化与CIN向CIN II/III和CIN II/III向宫颈癌的转变有关，可作为评估CIN进展风险的辅助生物标志物。此外，PAX1可能有助于确定不同阶段CIN患者的适当复查和治疗。
Objective The methylation of paired box gene 1 (PAX1) has a great influence on the process of cervical lesion. However, available evidence for the association between PAX1 methylation and cervical intraepithelial neoplasia (CIN) are inconsistent. Here, we systematically reviewed and analyzed PAX1 methylation in progress of CIN. Methods Two investigators independently searched eligible studies of PAX1 methylation and CIN that were published in PubMed, Cochrane Library, EMBASE, and Web of Science databases until November 30, 2016. We extracted clinicopathologic features of CIN and cervical cancel relevant to PAX1 methylation. Odds ratios (ORs) with their 95% confidence intervals (CIs) were used to assess the association between PAX1 methylation and progression of patients with CIN. Results Seven studies composed of 1055 patients with various stages of CIN and cervical cancel were eventually included. The results revealed that PAX1 methylation was associated with transition of CIN I to CIN II/III (OR, 0.09; 95% CI, 0.04–0.19) and CIN II/III to cervical cancer (OR, 0.16; 95% CI, 0.05–0.46), and similar results were produced in sensitivity analysis. Also, we found that the OR value was associated with average age and number of patients, publication year, and study location of included articles. Conclusions PAX1 gene methylation was associated with the transition of CIN I to CIN II/III and CIN II/III to cervical cancer, so that it could be an auxiliary biomarker to estimate the risk of CIN progress. Moreover, PAX1 may help to determine appropriate reexaminations and treatment for patients with various stages of CIN.